[
  {
    "ts": null,
    "headline": "FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)",
    "summary": "RAHWAY, N.J., September 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA® (pembrolizumab). Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. KEYTRUDA QLEX must be administ",
    "url": "https://finnhub.io/api/news?id=dc448aa5c1020cb609a4b6b5a84e7678080e70e7cc35ccb630b4d3ebaf6a5a00",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758321060,
      "headline": "FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)",
      "id": 136823488,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., September 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA® (pembrolizumab). Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. KEYTRUDA QLEX must be administ",
      "url": "https://finnhub.io/api/news?id=dc448aa5c1020cb609a4b6b5a84e7678080e70e7cc35ccb630b4d3ebaf6a5a00"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Merck's Cancer Drug Keytruda Injection",
    "summary": "FDA Approves Merck's Cancer Drug Keytruda Injection",
    "url": "https://finnhub.io/api/news?id=88d932a338e573e222562a3da43cc1024c26fbe4efa2ea5451a959de29c30c8f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758305400,
      "headline": "FDA Approves Merck's Cancer Drug Keytruda Injection",
      "id": 136868476,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "FDA Approves Merck's Cancer Drug Keytruda Injection",
      "url": "https://finnhub.io/api/news?id=88d932a338e573e222562a3da43cc1024c26fbe4efa2ea5451a959de29c30c8f"
    }
  },
  {
    "ts": null,
    "headline": "Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release",
    "summary": "Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release",
    "url": "https://finnhub.io/api/news?id=7d9e31de411a40e873a9eb484aaa0f298931066156333b502e248ff4a662c7d8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758303333,
      "headline": "Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release",
      "id": 136822477,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=7d9e31de411a40e873a9eb484aaa0f298931066156333b502e248ff4a662c7d8"
    }
  },
  {
    "ts": null,
    "headline": "Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?",
    "summary": "Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.",
    "url": "https://finnhub.io/api/news?id=62f099d987968db996f619d5b0762dcec0570e964c7089f4f358445834aa9c38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758300780,
      "headline": "Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?",
      "id": 136820667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.",
      "url": "https://finnhub.io/api/news?id=62f099d987968db996f619d5b0762dcec0570e964c7089f4f358445834aa9c38"
    }
  },
  {
    "ts": null,
    "headline": "Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?",
    "summary": "Bristol Myers ramps up a $2.5B restructuring plan to cut costs, streamline operations, and offset pressure from generic competition.",
    "url": "https://finnhub.io/api/news?id=bec503802a9be9cc127ad63c000bb5149415c0790f3e31905a8782af433cdc78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758294840,
      "headline": "Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?",
      "id": 136820024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Bristol Myers ramps up a $2.5B restructuring plan to cut costs, streamline operations, and offset pressure from generic competition.",
      "url": "https://finnhub.io/api/news?id=bec503802a9be9cc127ad63c000bb5149415c0790f3e31905a8782af433cdc78"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=36ac2bb3191b3aec546ead85a37fa2c73cff12c26fd08ae70aa34e48230cf587",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758290405,
      "headline": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know",
      "id": 136818305,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=36ac2bb3191b3aec546ead85a37fa2c73cff12c26fd08ae70aa34e48230cf587"
    }
  },
  {
    "ts": null,
    "headline": "Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season",
    "summary": "RAHWAY, N.J., September 19, 2025--Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of RSV in Infants During Their First RSV Season",
    "url": "https://finnhub.io/api/news?id=be94baefff26efca67f0859ae22555da899a1d2ff3098985fd8a651de9536d3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758282600,
      "headline": "Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season",
      "id": 136818306,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., September 19, 2025--Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of RSV in Infants During Their First RSV Season",
      "url": "https://finnhub.io/api/news?id=be94baefff26efca67f0859ae22555da899a1d2ff3098985fd8a651de9536d3c"
    }
  },
  {
    "ts": null,
    "headline": "Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer",
    "summary": "RAHWAY, N.J., September 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. One recommends approval of a new subcutaneous (SC) route of administration and a new pharmaceutical form (solution for injection) for KEYTRUDA® (pembrolizumab), which if approved would be marketed i",
    "url": "https://finnhub.io/api/news?id=87c5f3bde108dfe4d2da06cfb7b4cef28dd48c3bcbc6bd1f2820779e9d87db31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758282300,
      "headline": "Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer",
      "id": 136818307,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., September 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. One recommends approval of a new subcutaneous (SC) route of administration and a new pharmaceutical form (solution for injection) for KEYTRUDA® (pembrolizumab), which if approved would be marketed i",
      "url": "https://finnhub.io/api/news?id=87c5f3bde108dfe4d2da06cfb7b4cef28dd48c3bcbc6bd1f2820779e9d87db31"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca: Consistent Growth And Upcoming Catalysts Make This A Buy",
    "summary": "AstraZeneca is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. Click to read why AZN is a Buy.",
    "url": "https://finnhub.io/api/news?id=63c9970de83b73de6359dad980ea68cde4507b9840f7c6dc916a402fc1a3dead",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758274254,
      "headline": "AstraZeneca: Consistent Growth And Upcoming Catalysts Make This A Buy",
      "id": 136817825,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1250576655/image_1250576655.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. Click to read why AZN is a Buy.",
      "url": "https://finnhub.io/api/news?id=63c9970de83b73de6359dad980ea68cde4507b9840f7c6dc916a402fc1a3dead"
    }
  },
  {
    "ts": null,
    "headline": "3 FDA approval firsts that could be around the corner",
    "summary": "Several market-altering decisions are on the agency’s docket for the rest of 2025.",
    "url": "https://finnhub.io/api/news?id=ac85f9a48a9d77f43f31fbae8142d7c561989b990d0d72528e9573503a57ccad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758271318,
      "headline": "3 FDA approval firsts that could be around the corner",
      "id": 136818308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Several market-altering decisions are on the agency’s docket for the rest of 2025.",
      "url": "https://finnhub.io/api/news?id=ac85f9a48a9d77f43f31fbae8142d7c561989b990d0d72528e9573503a57ccad"
    }
  },
  {
    "ts": null,
    "headline": "Two positive opinions in the EU for Merck's Keytruda",
    "summary": "Merck announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted two positive opinions for Keytruda , its anti-PD-1 treatment.The first opinion...",
    "url": "https://finnhub.io/api/news?id=702ed3e8633d1781538d412ce1c703dbc1a940e75272a4df039bcae8af7744d8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758268764,
      "headline": "Two positive opinions in the EU for Merck's Keytruda",
      "id": 136817505,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted two positive opinions for Keytruda , its anti-PD-1 treatment.The first opinion...",
      "url": "https://finnhub.io/api/news?id=702ed3e8633d1781538d412ce1c703dbc1a940e75272a4df039bcae8af7744d8"
    }
  },
  {
    "ts": null,
    "headline": "Merck Gets Positive Opinions From Europe's CHMP on Keytruda, Enflonsia",
    "summary": "Merck Gets Positive Opinions From Europe's CHMP on Keytruda, Enflonsia",
    "url": "https://finnhub.io/api/news?id=35152dcdfe9300f6e49345dd2a9edba841d7317dbd5e3a4df9c58b13f0c109f6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758266040,
      "headline": "Merck Gets Positive Opinions From Europe's CHMP on Keytruda, Enflonsia",
      "id": 136868477,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck Gets Positive Opinions From Europe's CHMP on Keytruda, Enflonsia",
      "url": "https://finnhub.io/api/news?id=35152dcdfe9300f6e49345dd2a9edba841d7317dbd5e3a4df9c58b13f0c109f6"
    }
  }
]